Aarti Industries Q3 Revenue Jumps 11%, Taps Global Trade Shifts

CHEMICALS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Aarti Industries Q3 Revenue Jumps 11%, Taps Global Trade Shifts
Overview

Aarti Industries reported an 11% quarter-on-quarter revenue increase to Rs. 2,492 crore in Q3 FY26, driven by volume growth and higher capacity utilization. EBITDA also rose 11% to Rs. 323 crore. Despite Rs. 15 crore in exceptional expenses, PAT climbed 25% QoQ to Rs. 133 crore. The company achieved its highest-ever export share at 65%, benefiting from global trade realignments like the India-EU FTA, China's 'anti-involution' strategy, and the US-India trade deal. Strategic focus shifts towards advanced materials, with significant CAPEX planned for FY26.

Aarti Industries Charts Growth Path: Q3 Sees 11% Revenue Jump Amidst Global Strategy Shifts

📉 The Financial Deep Dive

  • The Numbers: Aarti Industries (AIL) reported Rs. 2,492 crore in revenue for Q3 FY26, an 11% increase quarter-on-quarter (Q-o-Q). EBITDA mirrored this growth, rising 11% Q-o-Q to Rs. 323 crore. Profit After Tax (PAT) saw a more substantial 25% Q-o-Q jump to Rs. 133 crore.
  • The Quality: The company achieved its highest-ever export revenue share of 65%, contributing to higher capacity utilization and better operating leverage. While overall Q-o-Q margins appear stable based on equal revenue and EBITDA percentage growth, specific segment pricing pressures in agrochemicals and pharmaceuticals were noted, offset by expectations of improvement due to China's 'anti-involution' strategy. An exceptional expense of Rs. 15 crore was booked for new labor code implementation. Operating cash flow for the nine months stood between Rs. 500-600 crore.
  • The Grill: Analysts probed the impact of US tariffs on key products like MMA and PDCB, with management clarifying the US-India trade deal is expected to improve realizations. The specifics of US export contributions for PDCB (15-20%) and MMA (50-60%) were discussed. The management also detailed how the removal of VAT subsidies on NCB chain products in China has already led to 7-10% price increases, supporting margin recovery expectations. The strategic rationale for MMA capacity expansion and the significant combined CAPEX for Zone 4 (Rs. 1,600-1,800 crore) were also points of discussion.

🚩 Risks & Outlook

  • Specific Risks: While structural tailwinds are positive, AIL faces ongoing pricing pressure in its agrochemicals and pharmaceuticals segments due to Chinese imports. Dependence on the US market for PDA products presents a risk, though the US-India trade deal is anticipated to mitigate this. A marginal increase in working capital, debt, and interest costs was observed due to higher export revenues.
  • The Forward View: Investors should monitor the execution of significant CAPEX projects, particularly the phased commissioning within Zone 4 and the capacity expansions for MMA and DCB. The company's pivot towards advanced materials signifies a strategic shift that will require diligent execution. The impact of international trade agreements and China's policy shifts on global pricing and AIL's margins will be crucial watchpoints in the next 1-2 quarters. The management anticipates significantly lower CAPEX in FY27 compared to FY26's Rs. 1,100 crore.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.